- Supported exchanges /
- F /
- 9Y4.F
RYVU THERAPEUTICS ZY-40 (9Y4 F) stock market data APIs
Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. The company has a research collaboration with Ncage Therapeutics Limited to develop next-generation antibody-drug conjugate (ADC) platform. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
RYVU THERAPEUTICS ZY-40 Financial Data Overview
10.92 | |
10.54 | |
- | |
10.92 | |
10.54 | |
10.54-15.32 | |
246 M | |
23 120 K | |
82 387 K | |
0.559 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
RYVU THERAPEUTICS ZY-40 Fundamental Data is available in our Financial Data APIs
- Net Revenue 82 387 K
- EBITDA -95 126 000
- Earnings Per Share -0.97
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get RYVU THERAPEUTICS ZY-40 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get RYVU THERAPEUTICS ZY-40 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: